PolarityTE, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard Hague
- Full Time Employees
- 42
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1960 South 4250 West Salt Lake City UT United States of America 84104
- IPO Date
- Aug 16, 1999
- CIK
- 0001076682
- Website
- polarityte.com
- Similar Companies
- Business
- PolarityTE, Inc. (now operating under the name RegenETP, Inc.) is a biotechnology company specializing in regenerative tissue products and biomaterials aimed at transforming patient care through innovative regenerative medicine solutions. The company's main product, SkinTE®, is an autologous heterogeneous skin construct designed to promote full skin barrier reconstitution by harvesting a small piece of the patient's own healthy skin tissue and manufacturing multi-cellular structures that accelerate and enhance healing. SkinTE® is developed for treating chronic wounds, including diabetic foot ulcers, and is currently under active investigation through pivotal clinical trials toward regulatory approval. PolarityTE’s product portfolio focuses on regenerative platforms for skin, bone, muscle, cartilage, and fat tissue regeneration, targeting unmet medical needs in chronic wound care and tissue repair. Recently, significant corporate changes include PolarityTE's acquisition of substantially all its assets by Grander Acquisition LLC in August 2023, which involved a strategic reorganization and the company’s renaming to RegenETP, Inc. This acquisition allowed the new leadership team to continue advancing SkinTE® through ongoing Phase III pivotal clinical studies required for a biologics license application for chronic cutaneous ulcer indications. In early 2025, the company announced the first subject screened in this pivotal Phase III study evaluating SkinTE® for Wagner Grade 1 diabetic foot ulcers. Additionally, SkinTE® received Breakthrough Therapy Designation from the U.S. FDA in February 2025, highlighting its potential as a novel treatment option. The company secured multiple rounds of funding including equity financing and senior secured credit facilities to support clinical development and operational growth. PolarityTE operates mainly from its headquarters in Salt Lake City, Utah, and serves the regenerative medicine and biotechnology sectors. It targets healthcare providers, clinical researchers, and patients with chronic wounds or tissue repair needs. The company focuses on leveraging autologous tissue engineering to provide dynamic, patient-specific regenerative solutions with potential applications spanning medicine, biomedical engineering, and material sciences. The transition to RegenETP marks a critical phase in its corporate and clinical strategy, emphasizing commercial-stage development and regulatory progress in the U.S. and potentially global markets. This comprehensive profile captures PolarityTE’s specialized product offerings and recent developments reflecting its strategic acquisition, name change, clinical advancements, and funding activities that underline its role in the regenerative medicine industry.
Commodities & Resources PTE Ltd. Announces Sale of Shares of Belmont Resources Inc.
Pioneering Technology Reports 2025 Q3 Financial Results
Commodities & Resources PTE Ltd. Announces Acquisition of Shares of Belmont Resources Inc. Pursuant to Private Placement
Commodities & Resources PTE Ltd. Announces Acquisition of Shares of Belmont Resources Inc. Pursuant to a Convertible Loan Agreement
Pioneering Technology Reports 2025 Q2 Financial Results
Momentum Builds for ScanTech AI Systems at PTE Madrid 2025 as Industry Embraces AI-Powered Security
International Assets Investment Management LLC Sells 1,464 Shares of GLOBALFOUNDRIES Inc. (NASDAQ:GFS)
AI Account Launches Asia's First Cloud-Based Accounting Solution Exclusively for SMEs
PolarityTE, Inc. (PTE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
PolarityTE, Inc. (PTE) Upgraded to Strong Buy: Here's What You Should Know
PolarityTE, Inc. (PTE) CEO Richard Hague on Q2 2022 Results - Earnings Call Transcript
PolarityTE to Attend H.C. Wainwright Global Investment Conference
PolarityTE (PTE) Stock: 1-For-25 Reverse Split Goes Into Effect
PolarityTE, Inc. (PTE) Reports Q1 Loss, Misses Revenue Estimates
PolarityTE, Inc. (PTE) CEO Richard Hague on Q1 2022 Results - Earnings Call Transcript
PTE Stock Soars 70% Following PolarityTE's New FDA Designation
10 Top Penny Stocks To Buy For Under $1 May 2022 Edition
Penny Stocks to Buy For Your Watchlist Next Week
How to Find the Best Penny Stocks to Buy in 2022
Best Penny Stocks To Buy Now? 5 Stocks Under $1 To Watch In April